- search hit 1 of 1
The theranostic promise for neuroendocrine tumors in the late 2010s – Where do we stand, where do we go?
Please always quote using this URN: urn:nbn:de:bvb:20-opus-170264
- More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading,More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.…
Author: | Rudolf A. Werner, Alexander Weich, Malte Kircher, Lilja B. Solnes, Mehrbod S. Javadi, Takahiro Higuchi, Andreas K. Buck, Martin G. Pomper, Steven Rowe, Constantin Lapa |
---|---|
URN: | urn:nbn:de:bvb:20-opus-170264 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Klinik und Poliklinik für Nuklearmedizin |
Medizinische Fakultät / Medizinische Klinik und Poliklinik II | |
Language: | English |
Parent Title (English): | Theranostics |
Year of Completion: | 2018 |
Volume: | 8 |
Issue: | 22 |
Pagenumber: | 6088-6100 |
Source: | Theranostics 2018; 8(22):6088-6100. doi:10.7150/thno.30357 |
Sonstige beteiligte Institutionen: | Johns Hopkins School of Medicine |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
GND Keyword: | Positronen-Emissions-Tomografie |
Tag: | PRRT; neuroendocrine tumor; peptide receptor radionuclide therapy; somatostatin receptor; theranostics |
Release Date: | 2018/12/21 |
EU-Project number / Contract (GA) number: | 701983 |
OpenAIRE: | OpenAIRE |
Collections: | Open-Access-Publikationsfonds / Förderzeitraum 2018 |
Licence (German): | CC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International |